PURPOSE: The objective of this work is to understand the sequence specificity of HAV peptides and to improve their selectivity in regulating E-cadherin-E-cadherin interactions in the intercellular junctions. METHODS: Peptide 1 was modified using an alanine scanning method to give peptides 2-6. The ability of these peptides to modulate intercellular junctions was evaluated using Madin-Darby Canine Kidney (MDCK) cell monolayers on Transwell membranes from either the apical (AP) or the basolateral (BL) side. Modulation of the intercellular junctions was measured by the ability to lower the transepithelial electrical resistance (TEER) of MDCK monolayers and by the increase in mannitol flux. Molecular docking experiments were performed to model the binding properties of these peptides to the EC1 domain of E-cadherin. RESULTS: Peptides 5 (Ac-SHAVAS-NH2) and 6 (Ac-SHAVSA-NH2) were found to be more effective than the parent peptide 1 in decreasing the resistance of the cell monolayer. Furthermore, comparative studies with the control and the weak inhibitor peptide 2 indicate that peptide 5 displayed a significant increase in mannitol flux. Molecular docking of peptides 1, 2 and 5 to the EC1 domain suggests that peptide 5 has the lowest binding energy. CONCLUSIONS: HAV peptides have the ability to modulate E-cadherin-E-cadherin interactions in the intercellular junctions of the MDCK cell monolayer, thus indirectly increasing the permeability of the tight junctions. This observation indicates that residues flanking the HAV sequence are important in the binding selectivity of HAV peptides to E-cadherin. Molecular docking can further aid in the design of peptides with better selectivity to the EC1 domain of E-cadherin.
PURPOSE: The objective of this work is to understand the sequence specificity of HAV peptides and to improve their selectivity in regulating E-cadherin-E-cadherin interactions in the intercellular junctions. METHODS: Peptide 1 was modified using an alanine scanning method to give peptides 2-6. The ability of these peptides to modulate intercellular junctions was evaluated using Madin-Darby Canine Kidney (MDCK) cell monolayers on Transwell membranes from either the apical (AP) or the basolateral (BL) side. Modulation of the intercellular junctions was measured by the ability to lower the transepithelial electrical resistance (TEER) of MDCK monolayers and by the increase in mannitol flux. Molecular docking experiments were performed to model the binding properties of these peptides to the EC1 domain of E-cadherin. RESULTS: Peptides 5 (Ac-SHAVAS-NH2) and 6 (Ac-SHAVSA-NH2) were found to be more effective than the parent peptide 1 in decreasing the resistance of the cell monolayer. Furthermore, comparative studies with the control and the weak inhibitor peptide 2 indicate that peptide 5 displayed a significant increase in mannitol flux. Molecular docking of peptides 1, 2 and 5 to the EC1 domain suggests that peptide 5 has the lowest binding energy. CONCLUSIONS: HAV peptides have the ability to modulate E-cadherin-E-cadherin interactions in the intercellular junctions of the MDCK cell monolayer, thus indirectly increasing the permeability of the tight junctions. This observation indicates that residues flanking the HAV sequence are important in the binding selectivity of HAV peptides to E-cadherin. Molecular docking can further aid in the design of peptides with better selectivity to the EC1 domain of E-cadherin.
Authors: Anna Maria Calcagno; Jennifer M Fostel; Eric L Reyner; Ernawati Sinaga; James T Alston; William B Mattes; Teruna J Siahaan; Joseph A Ware Journal: Pharm Res Date: 2004-11 Impact factor: 4.200
Authors: Maulik Trivedi; Jennifer S Laurence; Todd D Williams; C Russell Middaugh; Teruna J Siahaan Journal: Int J Pharm Date: 2012-04-17 Impact factor: 5.875
Authors: Marlyn D Laksitorini; Paul K Kiptoo; Ngoc H On; James A Thliveris; Donald W Miller; Teruna J Siahaan Journal: J Pharm Sci Date: 2015-01-12 Impact factor: 3.534
Authors: Paul Kiptoo; Ernawati Sinaga; Anna M Calcagno; Hong Zhao; Naoki Kobayashi; Usman S F Tambunan; Teruna J Siahaan Journal: Mol Pharm Date: 2010-12-17 Impact factor: 4.939
Authors: Ernawati Sinaga; Seetharama D S Jois; Mike Avery; Irwan T Makagiansar; Usman S F Tambunan; Kenneth L Audus; Teruna J Siahaan Journal: Pharm Res Date: 2002-08 Impact factor: 4.200
Authors: Kai Zheng; Jennifer S Laurence; Krzysztof Kuczera; Gennady Verkhivker; C Russell Middaugh; Teruna J Siahaan Journal: Chem Biol Drug Des Date: 2009-06 Impact factor: 2.817